Research programme: cancer therapeutics - neoX Biotech
Latest Information Update: 19 Feb 2021
At a glance
- Originator neoX Biotech
- Class Antineoplastics; Macromolecular substances; Polyclonal antibodies
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer